Title : Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.

Pub. Date : 2013 Feb

PMID : 23414467






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Importantly, as a MEK inhibitor, selumetinib could be particularly effective in tumors with a hyperactivated Ras/Raf/MEK/ERK pathway, which might be the case of KRAS-mutant non-small-cell lung cancers (NSCLCs). AZD 6244 zinc fingers and homeoboxes 2 Homo sapiens